EAM
EUCR

Exos Asset Management’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Exos Asset Management’s Portfolio EUCR Stock Details EUCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,485
Closed -$103K – 795
2021
Q2 		$103K Hold
10,485
– – 0.05% 330
2021
Q1 		$104K Buy
+10,485
New +$108K 0.08% 263

Other funds holding EUCR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Exos Asset Management's EUCR Position: Q3 2021 in Review

Exos Asset Management sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q3 2021, closing a stake of 10,485 shares — an estimated $103K sold.

Exos Asset Management first reported a position in EUCR in Q1 2021 and held it in 2 quarters. The position peaked at $104K in Q1 2021. 34 funds tracked by Wall St. Rank hold EUCR as of Q3 2021.

  • Exos Asset Management reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q3 2021 after selling out during the quarter.
  • Exos Asset Management sold 10,485 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q3 2021, an estimated $103K.
  • Exos Asset Management first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q1 2021 and held it in 2 quarters.
  • Exos Asset Management's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $104K in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q3 2021.

Based on Exos Asset Management's 13F filing for Q3 2021, filed 25 Oct 2021.